initi coverag
find alpha still possibl target
therapi portfolio
non-u analyst us disclosur credit suiss seek busi compani cover research report result investor awar firm may
conflict interest could affect object report investor consid report singl factor make invest decis
theme top catalyst
analyst evan
holt analysi sector
coverag univers approach
analyz sector
macro theme
launch coverag larg cap biotech
launch coverag larg cap biotech name
outperform amgen aimmun assumpt coverag
under-perform consensu call
posit sector think investor thought select stock
larg cap sentiment remain poor concern growth drug price recent phase failur
catalyst-driven smid cap stock favor specialist investor
think stock select alpha gener target therapi
examin state commerci busi
 like remain backdrop sector
fda new leadership see continu product measur drug approv innov
drug price overhang us elect potenti reform medicar part
allergy/immunolog novel oncolog neurosci migrain genom manipul
launch coverag transfer coverag vamil divan
also see industri note
evan seigerman cover
began career equiti research
deutsch bank cover us large-
cap sector
join credit suiss barclay
cover sector
prior career financ evan work
consult major biotechnolog
issu across organ
hold bba financ account
ross school busi univers
michigan ba spanish languag
literatur also univers michigan
charl martineau univers toronto lc stock recov highs/low late
earli investor seem cautiou approach
factset consensu valuat multipl forward p/e larg cap biotech set
sentiment around larg cap seem poor concern drug price growth recent phase failur
sentiment around smid cap better specialist posit around catalyst
valuat still rel near all-tim high acquisit premium higher ever good smid cap
charl martineau univers toronto biotech under-perform sinc boom
gone day buy basket major biotech name gener alpha
believ investor still find upsid discern
view exposur biotech focu target select approach pick stock
ytdbiotechbiotechlifesci toolss toolslifesci toolsservicesservicesequip/suptechnologyequip/suplifesci hcservicesequip/supservicess hcpharma equip/sup hc hc hc toolss charl martineau univers toronto credit suiss us larg cap biotech approach analysi
look
fundament underappreci mischaracter opportun
properli identifi quantifi address market
access factor
profit organiz structur measur via cash flow earn growth
abil deploy capit drive growth despit broader industri headwind via
organ innov support well-character biolog organiz expertis target unmet need
strateg synergist accret busi develop bd yield return buyer target
visibl achiev path realiz valuat target
catalyst strong impact predict time
proprietari research analys support these
expert call support view therapeut
physician survey multipl sclerosi asthma regeneron hiv gilead
differenti modeling- quantifi uk french opportun vertex
charl martineau univers toronto credit suiss us larg cap biotech approach valuat
think valuat
target price deriv risk-adjust product-specif sum-of-the-part discount cash flow
analysi alloc d/sg expens plu pipelin unalloc expens
assign probabl success base standard success rate literatur de-risk previou stage
specif program indic trial
forecast cash flow least year account impact known identifi competit patent
expir product launch beyond forecast period assess termin valu account organiz
capabl replac cash flow lost eros
discount rate base stage develop stage pre-clin earli late clinic commerci
compani assess risk achiev forecast
termin growth rate base assess busi end forecast period compani
abil replac cash flow lost eros
rare use multiples-bas valuat account chang busi length forecast
approach analyz sector
charl martineau univers toronto coverag univers glanc
consensu
market upside/ us pricepric downsid outperform rate bioscienc rate scienc rate stocksbiibbiogen picktickercompanyrel charl martineau univers toronto target therapi roadmap find alpha
break compani three area analysi
charl martineau univers toronto target therapi portfolio overview coverag
regeneron pipelin revenu gener subject collabor profit share agreement increment end-us sale necessarili get book revenu regeneron
revenuecompanyratingc busi strength total lead biosimilar oncolog migrain tbd allergy/ capac total busi weak total lead multipl sclerosi tbd gene therapi lag capac total busi weak total lead infecti diseas lag nash capac total busi strength total lead cystic fibrosi tbd gene therapi pain capac total busi strength total lead oncolog tbd net total potenti busi strength total lead neurosci tbd gene net total potenti busi strength total lead allergy/immunolog tbd oncologynmnmd ww end-us sale dupix libtayo busi strength total revenuenmnmpipelin lead peanut net total charl martineau univers toronto outperform rate stock rel rank
vertex differenti growth profil expect drive near-term cash flow also allow reinvest busi
support long-term growth think continu commerci execut pipelin updat guidanc revis support share
rel peer expect updat file full data set tripl combin therapi well continu progress toward
reimburs uk franc rest world drive upsid
proprietari work support thesi separ model uk franc opportun scenario analysi
neurocrin commercial-stag biotechnolog compani two market asset ingrezza tardiv dyskinesia td orilissa
endometriosi em market partner think ingrezza best-in-class treatment td expect drive revenu
earn growth next year see underappreci upsid potenti pipelin focus central nervou system
asset parkinson diseas opicapon gene therapi congenit adren hyperplasia among smid-cap coverag neurocrin
top pick due project strong revenu growth name ingrezza addit revenu stream orilissa solid pipelin
favor risk/reward proprietari work support thesi support expert physician discuss
view attract rel peer underappreci biosimilar busi could help chang project base busi
revenu declin rel stabil vs large-cap peer vari promis pipelin novel asset oncolog immunolog
compel valuat good balanc return capit sharehold repurchas dividend pipelin potenti abil yet
urgent need proprietari work support thesi asthma physician survey
aimmun current leader treatment peanut allergi late-st asset believ oral immunotherapi
like approv therapi reduc risk accident exposur children adult peanut allergi competitor aimmun
dbv least one year behind follow voluntari withdraw bla competit product viaskin peanut decemb
overal expect share continu outperform get closer launch expect late earli beyond
peanut allergi aimmun also pursu develop treatment egg allergi
neutral rate predic three main issu like base hiv busi see outsiz growth would significantli alter
earn project cell-therapi import platform sale yescarta unlik gener revenu akin sovaldi/harvoni
unlik under-perform think forward price-to-earnings multipl somewhat protect contract howev new
strateg vision acquisit could see expans
proprietari work support thesi hiv physician survey
begun find way back pipelin execut failur epacadostat howev need clinic evid trial
execut pipelin posit stock like jakafi franchis revenu growth profil see opportun fairli
valu find difficult point specif pipelin asset high convict clinic commerci perspect rel
smid-cap peer rate neutral think better pipelin risk/reward commerci busi upsid elsewher
whole view current valuat busi fair like compani focu innov expans pipelin
concern eylea could face increas headwind upcom launch novarti brolucizumab consensu forecast sanofi
collabor may high estim seem overst collabor profit
proprietari work support thesi asthma physician survey
life beyond aducanumab like remain challeng base busi like declin near term weak pipelin
like abl yield revenu earn growth ms expect increasingli competit major spinraza revenu
risk competit anticip signific share loss new sma spinal muscular atrophi incid novarti zolgensma long-term
believ ptc/roch risdiplam could take signific share preval sma market alzheim longer around focu investor
attent base busi eros like drive downsid manag priorit share repurchas could lead
multipl compress
proprietari work support thesi ms physician survey illustr scenario analysi spinraza franchis scenario analysi
charl martineau univers toronto macro theme
 usual remain constant backdrop larg cap biotech usual buyer smid cap
seller think pipelin hole need growth main driver key talk point
remaind
valuat come high make small mid-cap name attract view still
note hot area name -- target oncolog gene therapi -- recent premium paid suggest
asset competit high demand
dealstot deal valu take-out premium charl martineau univers toronto view potenti buyer target coverag
and/or need
and/or need
buyer
buyer
net cash
net cash
net cash
although posit neurocrin potenti acquisit target could see compani
engag smaller buyer busi develop broaden respect pipelin
estim deal capac base analysi current cash balanc debt capac project
next year account announc share repurchas
charl martineau univers toronto fda still pois product innov despit
departur commission gottlieb
fda remain integr compon biotechnolog
work manufactur help develop design clinic trial
increas focu biosimilar approv help lower healthcar cost
fda industri better align drug develop process
uptick fda
drug approv
estim
highest
number drug approv
year
nda
bla approv
rate nearli
strong experi
director nation
optimist
remain posit
factor biotech
ndasnm charl martineau univers toronto drug price health polici legisl unlik
drug price like overhang elect
see limit progress topic near term given split control hous senat
white hous
like see hh institut rebat reform medicar part plan
polici expert believ pbm stand lose rebat reform
compani abl reli less price increas drive revenu growth long term
current idea medicar part reform
reduc percent mark-up appli addit reimburs tie drug cost
propos yet implement
industri skeptic
part could close resembl part reimburs
privat insur compani would negoti directli manufactur use rebat tier
therapeut administ office/hospit set
solv issu rebat
current idea part reform
remov safe harbor allow pbm accept rebat manufactur
manufactur would compet list price instead opaqu rebat
could see elimin tradit rebat shift commerci market
charl martineau univers toronto regeneron eylea risk part reform
medicar part spend drug top
compani coverag risk
eylea highest spend
estim risk
estim risk
rituxan second-highest spend
exposur rituxan revenu
genentech/ roch jv
estim risk
us depart human servic
rankdrug manufacturercoverag compani spend liquidshire/ behr revenuecompani drug spend totaltotalat charl martineau univers toronto biogen tecfidera risk part reform
medicar part spend drug top
compani coverag risk
part reform
tecfidera spend
estim risk
sensipar spend
estim risk
harvoni spend
estim risk
us depart human servic
rankdrug manufacturercoverag compani spend flexpennovo flextouchnovo kwikpen revenuecompani drug spend totaltotalat charl martineau univers toronto balanc tailwind headwind biopharma
overal remain cautious optimist
uptick product appear pois
continu
signific valu alreadi assign pipelin
increas flexibl regul rapidli approv
payor environ continu becom
pipelin data product launch focu
increas public scrutini drug price
includ specialti care area
robust cash flow gener greater access
cash gener outsid us
continu increas gener util
biosimilar threat realiz
dividend yield defens mindset may
maintain interest support sector
rise interest rate cyclic recoveri may
bode well rel defens sector
charl martineau univers toronto theme top catalyst
charl martineau univers toronto top catalyst watch next month
companydrugindicationdescriptiontim frameamgenamg oral kra solid tumorsphas clinic data ascoasco combin cystic fibrosisasset select phase data decis court case vs amgenrepathahypercholesterolemiadistrict court decis perman injunct follow second juri trial patent approv approv brolucizumaboct lymphomaphas data ehajun arthritissubmiss therapi nash treatmentatla trial read out phase data fxr allergi fda advisori committe data like esmo sclerosismylan ipr decis patentearli ruxolitinibatop dermatitisphas data readout earli fibroidssnda approv fibrosisupd uk franc reimbursementtbd charl martineau univers toronto allergi immunolog market remain immatur
atop dermat asthma
market
dermat
compel therapi review
compel therapi review
safeti advers event data
respond
respond
regeneron dupixentasthma
suggest dupix
compel efficaci safeti
dermat vitiligo
ra moder -sever psoriasi moder -sever ulcer coliti moder -sever crohn moder -sever atop dermat moder -sever asthma ww market us moderate/sever maturityapprov agent per target tnf-alpha clinic per target btk receptor receptor charl martineau univers toronto novel oncolog pois address difficult-to-treat tumor
type extend life reduc burden cancer
broad pipelin address high valu target
bispecif target bcma multipl myeloma
increment sale per asset
differ approach car-t
regeneron potenti leverag across multipl
libtayo market cutan small cell
carcinoma seek approv non-smal
bispecif target bcma ovarian
gilead car-t innov franchis field
increasingli competit slow uptak
still play catch epacadostat failur
oncolog market expect grow
driven mainli merck bristol
growth driver
still expect see increas use
addit approv car-t bispecif
charl martineau univers toronto focu gilead
overal think quieter meet cover compani
initi clinic data earli abstract indic two patient partial respons
safeti accept patient report treatment- relat
yet determin concern rais call
take data earli make call sign anti-tumor activ
bcma bite multipl myeloma abstract
updat data present although abstract note februari
respons last year
respons rate previous report
capmatinib met inhibitor partner novarti abstract
addit data present geometri nsclc
abstract suggest deep durabl respons manag toxic
earli data phase trial studi asset r/r
trial-in-progress poster limit updat
charl martineau univers toronto novel neurosci therapi progress
ingrezza tardiv dyskinesia key revenu driver
ingrezza could reach peak sale
pipelin diversif gene therapi
collabor voyag therapeut
multipl sclerosi franchis remain core
compon base busi near term long-
term headwind exist novarti mayzent
celgen ozanimod roch ocrevu
satisfact use treatment-
experienc patient share captur
biogen tysabri inject
sma biogen remain leader expect
signific competit novarti zolgensma
roche/ptc risdiplam bull/base/bear
case present next slide
end-us sale ms ww csm ww end-us sale ingrezza sale csingrezza sale consensuscagrc charl martineau univers toronto spinraza scenario analysi three case biogen
base casepeak sale
lose major share newli diagnos
market zolgensma
risdiplam captur preval
bear casepeak sale
lose major share newli diagnos
market zolgensma
risdiplam take major share
bull casepeak sale
lose major share newli diagnos
market zolgensma
risdiplam approv henc retain
market share preval market
spinraza ww unadjust sale base spinraza ww spinraza ww unadjust sale bear spinraza ww ww unadjust sale bull spinraza ww charl martineau univers toronto migrain renew focu recent launch cgrp
aimovig remain leader despit crowd
commerci landscap anti-cgrp market
slower growth compar competitor
clear competit edgeclin data
competit threat oral cgrp
payer coverag still biggest hurdl
payer coverag cgrp
market share
monthli month sinc pbmprefer formularynon-pref formularyexclusioncov live pbmexpress script aimovig amgn/nv emgal ajovi million caremark ajovi teva emgal -aimovig millionoptumrx unitedcar aimovig amgn/nv emgal ajovi charl martineau univers toronto gene therapi gene edit leader coverag
program could provid pipelin upsid near term
none coverag
nightstar acquisit interest
see difficulti commerci
headwind novarti zolgensma gene
therapi biogen spinraza sma
vertex crispr partnership sickl cell
diseas beta thalassemia earli stage
first patient dose februari
potenti competit bluebird bio
pipelin diversif data still earli
friedreich ataxia earlier lead candid
expect
first patient parkinson diseas indic
high consensu estim revenu growth
look deal space given
focu person medicin
expect continu invest could see
even clinic data across indic
charl martineau univers toronto company-specif overview tear sheet
initi coverag outperform rate base view
vertex differenti growth profil drive near-term cash
flow also allow reinvest busi support long-term
growth think continu commerci execut pipelin updat
guidanc revis support share rel peer expect
updat file full data set tripl well continu progress
toward reimburs uk franc rest world drive
next month expect continu progress
commerci front cf development updat tripl
potenti updat earlier pipelin continu commerci
execut main-driv near-term upsid view detail
surround regulatori file tripl decis tripl
combin bring forward full data set potenti fall
nacfc meet could also support stock beyond cf updat
potenti initi data patient treat could provid
share price appreci
reimburs agreement england franc
continu penetr market rest-of-world under-
appreci revenu opportun like drive upsid uk
largest concentr cf patient world approxim
world popul thu repres
signific revenu opportun formal agreement franc would
also like drive share upsid predict exactli
agreement would reach think recent progress vertex
uk govern posit indic
one-year price target base base-cas risk-
adjust dcf analysi assign po tripl
combin likelihood reimburs deal uk
franc
 strength capac charl martineau univers toronto vertex pharmaceut outperform target price
vertex best earn revenu growth
profil among large-cap biotech pharma
high price-to-earnings function recent becom
profit basi rel cost
earn growth far less peer
follow recent interact uk parliament
think agreement nh get
closer agreement would provid upsid
revenu uk franc essenti
near-term thesi
non-cf pipelin free call option limited-
to-no valu ascrib pain crispr
vrtx price-to-earnings high
support upsid
compani still earli stage
ratio large-cap
biotech peer pharma
vertex price-to-earnings high warrant
continu multipl expans cash-
flow earn potenti fairli
ou reimburs
vertex gain broad reimburs
tougher govern particularli uk
franc
vertex continu experi
difficulti obtain ou
reimburs fail reach
agreement uk franc
valuat non-cf
vertex diversifi pipelin high-
valu therapeut area like
gener near-term share upsid
like posit data updat
pipelin beyond cf immatur
like over-valu market
assetindicationmilestonetimingimportancetripl combin cystic top-line combin cystic fibrosismolecul select nda fibrosisfda approv age combin cystic fibrosisnda combin cystic fibrosisful data present oct fibrosisema submiss age follow bunionectomyphas dose rang studi gene-editingupd initi recruit next-gen cystic fibrosisphas proof-of-concept studi qd regimen cystic fibrosisphas proof-of-concept studi charl martineau univers toronto neurocrin bioscienc inc outperform target price
neurocrin commercial-stag biotechnolog compani two market asset ingrezza tardiv
dyskinesia td orilissa endometriosi em market partner think ingrezza
best-in-class treatment td expect like drive revenu earn growth next
year see underappreci upsid potenti central nervou system focus pipelin asset
parkinson diseas opicapon gene therapi congenit adren hyperplasia among smid-
cap name neurocrin top pick due project strong revenu growth name ingrezza
addit revenu stream orilissa solid pipelin favor risk/reward
ingrezza best-in-class therapeut td blockbust
potenti think on-going launch ingrezza like
remain strong forecast potenti sale earli
vari pipelin favor risk/reward neurocrin pipelin
asset stage develop pre-clin phase
like option asset note like fda
approv opicapon pivot studi begin
accord compani updat recent
ink gene-therapi partnership voyag
orilissa could market leader endometriosi
uterin fibroid given unmet medic need first-to-
market posit market believ could
one-year price target base base-cas risk-adjust
dcf analysi assign po opicapon nbi-
orilissa uterin fibroid
 strength net potenti charl martineau univers toronto neurocrin bioscienc inc outperform price
ingrezza tardiv
differenti competit
market penetr provid long term
upsid strong share acquisit
neurocrin may fail increas physician
decreas payer restrict may
hamper growth usag
ingrezza continu revenu growth driver
neurocrin due superior profil simplifi
dose titrat believ
better safeti profil believ consensu
estim conserv
orilissa endometriosi
uterin fibroid
orilissa could potenti second-
line treatment choic moderate-to-
sever em due similar efficaci
greater conveni fewer side
increas competit relugolix
sale due undifferenti therapi
gnrh antagonist market
efficaci data elagolix relugolix linzagolix
rel similar clear favorit exist
market larg enough three player clinic
adopt like base superior market
formulari adopt drive brand prefer
upsid potenti
pipelin
opicapon could therapi
choic levodopa extend
provid addit upsid market
signific unmet need
long-term use opicapon could prove
unsaf smaller expect
uptak could occur due ineffect
commerci earli
stage minim support data
opicapon potenti best-in-
class comt inhibitor proven efficaci
toler side effect conveni dose
rel drug class competitor posit
data provid confid
adren hyperplasiafda meet adult pivot diseasephas long-term data diseasenda file fibroidssnda adren hyperplasiaphas initi adren hyperplasiapivot trial announc diseasecomplet phase trial ataxialead candid fibroidssnda approv diseasenda approv commerci charl martineau univers toronto amgen inc outperform target price
attract rel peer underappreci biosimilar busi could help chang project base busi revenu
declin rel stabil vs large-cap peer vari promis pipelin novel asset oncolog immunolog compel
valuat good balanc return capit sharehold repurchas dividend pipelin abil yet urgent need
thesi grow biosimilar busi
view anchor next leg revenu growth even base busi
declin see potenti global gener sale
view franchis help mitig replac lost
revenu current base busi
oncolog pipelin amgen novel oncolog pipelin price
could provid signific addit upsid clinic data readout
harder quantifi like broad oncolog platform asset
address high-valu target area unmet medic need updat
oncolog pipelin could provid sourc upsid catalyst
near mid-term
price discount current trade price-to-earnings discount
 vs ep factset estim major pharma
peer merck lilli slow
eros base busi well known potenti
repres current valuat
note figur may sum total due round credit suiss estim
one-year price target base base-cas risk-adjust
dcf analysi assign po pipelin biosimilar
mvasi
 strength capac charl martineau univers toronto amgen inc outperform target price
stock
expens rel
trade higher forward
earn multipl peer
pharma peer
rel expens
base busi trade
in-lin large-cap peer
think trade least in-lin
major pharma slight premium given
underappreci biosimilar busi upsid
asthma broad novel oncolog pipelin
evolut
expect biosimilar busi
aimovig novel oncolog pipelin
fulli reflect estim
even tezepelumab could
eros base busi
appreci street launch
aimovig also strong expect
furthermor unabl
project similar declin base busi vs
consensu howev biosimilar could
make revenu declin base busi
potenti revenu aimovig even
upsid potenti
pipelin
could see posit data
tezepelumab
asthma omecamtiv mecarbil
pipelin failur continu compress
multipl stock begin
trade discount biotech
diversif heme-onc
addit car-t asset
assetindicationmilestonetimingimportanceamg tumorsphas clinic data ascoasco ascoasco osteoporosischmp opinion immunologybsufa arthritisdecis court case vs praluent patent top line osteoporosisema breast cancerbsufa cll raphas top line data myeloid leukemiaphas initi clinic acut myeloid leukemiaphas updat clinic myelomaphas initi clinic data acut myeloid leukemiaphas initi clinic myelomaphas initi clinic charl martineau univers toronto aimmun outperform target price
aimmun current leader peanut allergi treatment space late-st asset given current clinic data set believ
oral immunotherapi like approv therapi reduc risk accident exposur children adult peanut
allergi competitor aimmun dbv therapeut least one year behind follow voluntari withdraw bla
competit product viaskin peanut decemb overal think share continu outperform get closer launch
expect late earli beyond peanut allergi aimmun also pursu develop treatment egg
view aimmun rel biotech peer
aimmun current revenu commerci
begin next year expect gener
revenu compani unadjust potenti sale
product revenu
 perspect believ aimmun
acquisit target posit strength
asset like approv near-term
compani could acquir prior approv shape
commerci trajectori asset
risk clinic development lead asset
regulatori fda/ema may approv
product commerci much valuat base
futur sale supplier aimmun reli
singl supplier peanut protein external/ market
biotech remain volatil sector could impact
one-year price target base base-cas risk-adjust
dcf analysi assign po
outlook neutral three main reason like base hiv busi see outsiz growth would significantli alter earn
project cell-therapi import platform sale yescarta like never gener revenu akin sovaldi/harvoni
unlik under-perform think multipl somewhat protect contract new strateg
vision acquisit could see expans
multipl unlik contract rel
peer pay growth gilead share trade warrant
forward price-to-earnings discount larg cap biotech peer think hiv
hcv fairli valuedeven dominant-shar hiv like
continu per physician check proprietari survey yescarta
cell therapi franchis repres interest innov howev
continu believ commerci remain challeng
past readout fairli confid
filgotinib leader immunolog space follow posit
data see limit downsid risk current trade level howev
pend clariti stori evolv back growth
expect signific multipl expans near term
strong strateg prioriti yet wait execut first
glimps oday earn call got sens
understand urgenc fill later-stag pipelin submit market
applic filgotinib soon possibl focu commerci
deliveri think right strateg approach
commerci front think effort acceler sale yescarta
would seen posit think formal separ kite
distinct busi unit could help foster innov akin roch
handl genentech
one-year price target base base-cas risk-adjust
dcf analysi assign blend po filgotinib across
multipl indic valu on-going nash program
 weak capac charl martineau univers toronto gilead scienc neutral target price
durabl hiv
expans cell
gilead continu remain domin
player hiv busi driven
biktarvi gener unabl dent
sale durabl growth viiv
gilead market share heavili impact
brand gener competit
greater-than-expect uptak
patient less expens option
per physician check survey believ
gilead remain domin hiv gener impact
limit us in-lin expect
ou limit impact viiv doublet survey
yescarta beat expect driven
manufactur improv label
next-gen therapi kite
allogenic-bas platform
yescarta sale continu lag gilead
unabl expand current pi
yescarta gilead unabl develop
cell therapi forc write
kite acquisit
believ yescarta sale continu
modest minim expans
indic due strong competit long
run kite platform could import
gilead though hard justifi price
daniel oday abl success
navig gilead top bottom-lin
earn growth intern restructur
acceler cell-therapi
franchis extern
daniel oday big-pharma style
leadership clash gilead biotech
mental deliv
reacceler revenu earn
given oday track record roch believ
effect leader get
sens appreci urgenc bolster
later-stag pipelin look see
execut strategi recent outlin
data present data present adult phase data present pediatr data phase phase pivot studi phase phase registr phase studi mab data phase combin studi enrol pivot phase charl martineau univers toronto incyt corpor neutral target price
begun find way back pipelin execut failur epacadostat howev need clinic evid trial
execut pipelin posit stock like jakafi franchis revenu growth profil think opportun
fairli valu find difficult point specif pipelin asset high convict clinic commerci perspect
rel smid-cap peer rate neutral think better pipelin risk/reward commerci busi upsid elsewher
jakafi franchis drive growth
estim sale yet flow fairli
valu debat strength jakafi franchis
like remain best-in-class inhibitor two rare blood
cancer also think clinic data seen thu far
itacitinib steroid-nav graft vs host diseas gvhd compel
believ opportun much smaller jakafi rare blood
oncolog pipelin vari yet bulk clinic data
immatur meaning valuat rebuild pipelin
oncolog rel strong view think mani
asset earli meaning valuat pemigatinib
shown efficaci rare bile-duct cancer opportun appear
modest would compet larger bladder
dermatolog franchis may better posit out-
licens asset topic ruxolitinib could effect treatment
varieti immune-medi dermatolog condit think
could out-licens asset sell topic dermatolog
drug differ vs oncolog could unlock valu
bolster oncology-focus pipelin
one-year price target base base-cas risk-adjust
dcf analysi assign po jakafi gvhd
pemigatinib cholangiocarcinoma po topic ruxolitinib
po itacitinib gvhd pemigatinib bladder cancer
 strength net potenti charl martineau univers toronto incyt corpor neutral price
expect
opportun
jakafi well posit mf
pv space like upsid
steroid-refractori gvhd itacitinib also
well posit take share
limit upsid exit jakafi mf
pv gvhd opportun
smaller compani street
expect itacitinib opportun also
smaller expect
think jakafi solid drug like
reach us peak sale yet think
upsid fairli valu believ market
like smaller expect gvhd jakafi
itacitinib
multipl shot goal
mani focu
asset pemigatinib fgfr
mutat tumor capmatinib
nsclc could drive next leg
growth despit prior failur
market pemigatinib small
cholangiocarcinoma furthermor drug
face competit js balversa
bladder cancer capmatinib entitl
royalti novarti
like pemigatinib drug face competit
econom capmatinib control
novarti like multipl shot goal think
oncolog pipelin rel immatur
warrant higher valuat current assign
diversif
provid interest upsid given
believ grow atop
dermat market unmet need
develop dermatolog asset
distract incyt organ
core oncolog focu
baricitinib like limit usag ad
dermatolog franchis best posit
out-licens opportun core
compani current oncolog focu baricitinib
viabl ad asset given toxic
emerg competit landscap ad
assetdiseasemilestonetimingimportancejakafi ruxolitinib gvhd steroid-refractori acutepdufa ruxolitinibvitiligophas data readout upcom medic cell lung cancernda submiss novarti data present submiss ruxolitinib gvhd steroid-refractori acutetoplin data readout ruxolitinib gvhd steroid-refractori chronictoplin data readout treatment-nav acutetoplin data readout baricitinib atop dermatitisphas data present breeze-ad like treatment-nav chronictri initi agnosticphas trial initi ruxolitinibvitiligophas initi ruxolitinibatop dermatitisphas data readout earli charl martineau univers toronto regeneron pharmaceut neutral target price
think whole current valuat fairli valu busi like compani focu innov expans pipelin
concern eylea could face increas headwind upcom launch novarti brolucizumab sanofi collabor consensu
forecast may high estim seem overst collabor profit
eylea growth expect slow market satur competit
novarti expect earli eylea
enjoy posit marker leader think near-term launch
novarti brolucizumab could disruptor assum share
loss wamd chang way medicar part drug
reimburs could impact eylea sale significantli eylea highest
total spend product could see shift reimburs
part even usag intern price index price think
substant polici chang unlik highlight risk
long-term consensu expect dupix revenu
sanofi collabor may high proprietari
survey indic physician enthusiasm dupix asthma longer-
term revenu number like account competit asthma
see potenti competit amgen/astrazeneca tezepelumab
show impress efficaci phase ad expect
competit novel jak inhibitor may safer previou
gener consensu collabor revenu forecast view
unrealist high forecast collabor revenu
constant issu given complex partnership limit
visibl profit driver revenu miss
one-year price target base base-cas risk-adjust
dcf analysi assign po dupix nasal polyp
eoe libtayo nsclc cervic cancer
end-us sale subject collabor profit share agreement
necessarili book regeneron revenu
 strength capac charl martineau univers toronto regeneron pharmaceut neutral target price
eylea continu grow despit
take minim share launch
dupix second flagship asset
regeneron truli pipelin within
ad asthma nasal polyp eoe
minim competit
eylea sale strongli impact
share biosimilar also impact usag
eylea physician payer opt
less-expens altern
see slow eylea growth due market
satur potenti launch competitor
forecast consensu sale beyond
brolucizumab biosimilar moder
impact eylea sale go forward
sale dupix fail acceler due
competit threat ad asthma
mix data nasal polyp eoe
limit upsid opportun drug
dupix differenti drug ad
asthma consensu expect like
high behind
dupix see competit novel jak
inhibitor ad tezepelumab asthma
libtayo strong gateway asset io
regeneron cscc small
could see addit upsid
indic collabor
pipelin asset provid upsid
libtayo sixth
approv small indic
regeneron sanofi miss
boat io allianc
libtayo could produc least sale
across cscc cervic basal cell
carcinoma data
encourag cautious optimist
bcma collabor program
assetindicationmilestonedateimportancedupixentcrswnppdufa sbla approv regulatori decis novarti wamdpdufa approv wamd novartisoct dermatitisphas pediatr year old top top line data studi phase potenti lymphomainiti studi phase potenti studi phase charl martineau univers toronto biogen under-perform target price
life beyond aducanumab like remain challeng base busi like declin near term weak pipelin
like abl yield revenu earn growth ms expect increasingli competit major spinraza revenu
risk competit anticip signific share loss new sma incid novarti zolgensma long-term believ ptc/roch
risdiplam could take signific share preval sma market alzheim longer around focu investor attent base busi
eros like drive downsid manag priorit share repurchas could lead multipl compress
unclear path forward aducanumab failur face
believ clear challeng establish execut
strateg path forward past year share price
close tie increment updat alzheim diseas ad think
without ad program growth stori remain
murki meaning de-risk pipelin asset recent
manag commentari indic priorit share
repurchas expect multipl compress
greater proport cash flow return sharehold rather
reinvest growth
major spinraza revenu risk competit
see direct competit novartiss gene therapi product zolgensma
could use primari treatment newli diagnos patient
replac ahead biogen spinraza gene therapi could
differenti single-tim dose compar chronic administr
spinraza think spinraza incid market newli
diagnos patient type sma like shift zolgensma
especi on-going implement newborn screen sma
long-term preval market risk roche/ptc
risdiplam believ oral option would strongli prefer
intrathec inject given compar efficaci view
revenu risk zolgensma risdiplam under-appreci
one-year price target base base-cas risk-adjust
dcf analysi assign po vumer ms base
case assum spinraza lose major share sma
incid market zolgensma split remain
preval opportun risdiplam
 weak capac charl martineau univers toronto biogen under-perform target price
competit sma
see upsid spinraza
despit gene therapi launch
success pipelin continu
durabl ms franchis despit
face headwind across
commerci busi sma ms
biosimilar pipelin bd effort fail
re-acceler growth lead
multipl compress
impact headwind across base busi
magnifi investor littl els focu near-
term despit view urgent need acquir
growth manag recent emphas belief
share repurchas best use capit
competit zolgensma less
anticip risdiplam either fail trial
significantli less efficaci
spinraza sale peak
remain durabl long term
zolgensma abl take nearli
entir share newli diagnos infant
driven newborn screen risdiplam
replac spinraza standard-of care
preval market
believ full impact lose
incid market bake number
risdiplam shown good efficaci thu far
potenti replac spinraza preval
market especi sma type
success across near-term pipelin
pain vixotrigin nightstar asset
posit pipelin updat continu
near-term pipelin fail deliv
revenu growth either due failur
clinic commerci under-perform
forc write
nightstar purchas
believ current pipelin
drive upsid asset highlight compani
limit data unsuccess trial
nightstar asset like small market
meaning affect
assetdiseasemilestonetim importancebiogen catalystsvumer sclerosisfda sclerosismylan ipr decis natalizumab epilepsyphas top data parkinson diseasephas top line data alsphas top line choroideremiaphas top line phase top line datal retin pigmentosaphas top line datatbdmediumcompetitor catalystszolgensma novarti smapdufa bla approvalmay ptc/roch smanda file charl martineau univers toronto holt analysi larg cap biotech
charl martineau univers toronto biotech second conserv market impli expect
healthcar sub-industri second attract valuat
return capit cfroi histor forecast market impli
current price impli declin return
current price impli increas return
spread ntm forecast return capit vs market-impli
holt market impli cfroi quantifi futur level return capit requir valid today price
market expect consensu forecast indic attract valuat vice-versa
charl martineau univers toronto accord holt aggreg econom yield us biotech never
cheap rel us healthcar past year
holt econom yield proxi oper free cash flow yield invers holt econom pe higher yield
indic cheaper valuat question regard sustain futur cash flow
charl martineau univers toronto holt capit deploy trend assess show gilead
activ seem deploy excess cash share
buyback compani coverag deploy cash
capit deploy trend total cash deploy
author report evan seigerman would like acknowledg
contribut work matthew terwelp md adrian
garcia associ credit suiss larg cap biotechnolog equiti
charl martineau univers toronto biotech becom less expens forward price-to-earnings basi
forward price-to-earnings larg cap biotech vs us pharma
biotech
lower
price-to-earnings
lower
price-to-earnings
factset larg cap biotech celg note year exclud vertex due period net loss per share us
p/elarg cap biotechu charl martineau univers toronto vertex under-valued basi
higher price-to-earnings rel
vertex sole basi
price-to-earnings fail fulli valu
strength busi
growth profil abil
compani invest
vertex lowest
ratio compar larg cap
biotech us pharma
less expens forward-
upsid opportun
share rel
peer next month
cap etfss nasdaq biotechnolog charl martineau univers toronto investor appetit biotech still exist
cadenc ahead ipo deal may vs may
offer datecompani nameoff price rangeoff pricepricingrangegross proce market cap deal performanceperform inc pharma scienc scienc inc charl martineau univers toronto short interest larg cap tech coverag
short interest larg cap biotech
regeneron highest short interest larg cap coverag
gilead lowest
neurocrin highest short interest
lower
aimmun short interestth highest coverag
high fund outflow
less fund flow past month
charl martineau univers toronto credit suiss coverag univers valuat
cover larg cap biotechnolog inc amgnevan scienc inc gildevan incorporatedvrtxevan inc biibevan inc regnevan mid cap biotechnologyalexion inc alxnmartin corporationincyevan inc bmrnmartin inc srptmartin inc nbixevan corporationuthrmartin incaimtevan major johnson johnsonjnjvamil inc pfevamil co inc mrkvamil lilli companyllyvamil inc abbvvamil squibb companybmyvamil charl martineau univers toronto compani mention price aimt oq inc amgn oq inc biib oq gilead scienc inc gild oq incyt corpor inci oq inc nbix oq regeneron inc regn oq vertex inc vrtx oq disclosur appendix analyst certif evan seigerman certifi view express report accur reflect person view subject compani secur part compens directli indirectli relat specif recommend view express report decemb analyst stock rate defin follow outperform stock total return expect outperform relev benchmark next month neutral stock total return expect line relev benchmark next month under-perform stock total return expect under-perform relev benchmark next month relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres attract neutral less attract underperform least attract invest opportun octob canadian well european rate base stock total return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex index prior octob canadian rate base stock absolut total return potenti current share price rel attract stock total return potenti within analyst coverag univers australian new zealand stock expect total return calcul includ roll dividend yield outperform rate assign greater equal under-perform less equal neutral may assign overlap rate rang allow analyst assign rate put context associ risk prior may rang outperform under-perform rate overlap neutral threshold oper juli restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun includ invest recommend cours credit suiss engag invest bank transact certain circumst rate nr credit suiss equiti research invest rate view stock secur relat compani time cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view equiti secur compani relat product volatil indic stock defin volatil stock price move month least past month analyst expect signific volatil go forward analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat sector rel group histor fundament and/or valuat overweight analyst expect sector fundament and/or valuat favor next month market weight analyst expect sector fundament and/or valuat neutral next month underweight analyst expect sector fundament and/or valuat cautiou next month analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector credit suiss distribut stock rate bank client global rate distribut rate versu univers bank client outperform/buy bank client neutral/hold bank client underperform/sel bank client restrict purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform close correspond buy hold sell respect howev mean stock rate determin rel basi pleas refer definit investor decis buy sell secur base invest object current hold individu factor import global disclosur credit suiss research report made avail client proprietari research portal cs credit suiss research product may also made avail third-parti vendor altern electron mean conveni certain research product made avail cs servic provid credit suiss analyst client may depend specif client prefer regard frequenc manner receiv commun client risk profil invest size scope overal client relationship firm well legal regulatori constraint access credit suiss research entitl receiv time manner pleas contact sale repres go http //plu credit-suiss com credit suiss polici updat research report deem appropri base develop subject compani sector market may materi impact research view opinion state herein credit suiss polici publish invest research imparti independ clear fair mislead detail pleas refer credit suiss polici manag conflict interest connect invest research http //www credit-suiss com/sites/disclaimers-ib/en/managing-conflict html inform relat tax statu financi instrument discuss herein intend provid tax advic use anyon provid tax advic investor urg seek tax advic base particular circumst independ tax profession credit suiss decid enter busi relationship compani credit suiss determin involv develop manufactur acquisit anti-personnel mine cluster munit credit suiss posit issu pleas see http //www credit-suiss com/media/assets/corporate/docs/about-us/responsibility/banking/policy-summaries-en pdf analyst respons prepar research report receiv compens base upon variou factor includ credit suiss total revenu portion gener credit suiss invest bank activ compani mention section full compani name credit suiss current within past month follow invest bank client amgn oq biib oq credit suiss provid invest bank servic subject compani amgn oq biib oq within past month within last month credit suiss receiv compens non-invest bank servic product follow issuer amgn oq within past month credit suiss receiv compens invest bank servic follow issuer amgn oq credit suiss expect receiv intend seek invest bank relat compens subject compani aimt oq amgn oq biib oq inci oq within next month credit suiss current within past month follow issuer client servic provid non-investment-bank securities-rel amgn oq credit suiss current within past month follow issuer client servic provid non-investment-bank non securities-rel amgn oq credit suiss member credit suiss group market maker liquid provid secur follow subject issuer aimt oq amgn oq biib oq gild oq inci oq regn oq vrtx oq member credit suiss group parti agreement may provid servic set section annex direct european parliament council mifid servic subject issuer amgn oq biib oq regn oq within past month date time product dissemin histori recommend subject compani featur report dissemin within past month pleas refer link import region disclosur singapor recipi contact credit suiss ag singapor branch matter aris research report analyst involv prepar report may particip event host subject compani includ site visit credit suiss accept permit analyst accept payment reimburs travel expens associ event credit suiss secur canada inc polici procedur regard dissemin equiti research pleas visit http //www credit-suiss com/sites/disclaimers-ib/en/canada-research-polici html investor note incom secur financi instrument may fluctuat price valu secur instrument may rise fall case investor may lose entir princip invest research report author credit suiss secur usa llc evan seigerman import credit suiss holt disclosur holt methodolog assign rate target price secur analyt tool involv use set proprietari quantit algorithm warrant valu calcul collect call holt valuat model consist appli compani includ databas third-parti data includ consensu earn estim systemat translat number default variabl incorpor algorithm avail holt valuat model sourc financi statement price earn data provid outsid data vendor subject qualiti control may also adjust close measur underli econom firm perform adjust provid consist analyz singl compani across time analyz multipl compani across industri nation border default scenario produc holt valuat model establish warrant price secur third-parti data updat warrant price may also chang default variabl may also adjust produc altern warrant price could occur warrant price algorithm output appli systemat across compani base histor level volatil return addit inform holt methodolog avail request cfroi cfroe holt holt len holtfolio clariti confid power holt trademark regist trademark credit suiss group ag affili ed state countri holt corpor perform valuat advisori servic credit suiss credit suiss group ag subsidiari affili right reserv import disclosur regard compani subject report avail call import disclosur except valuat methodolog risk discuss also avail credit suiss disclosur websit http //rave credit-suiss com/disclosur valuat methodolog risk associ recommend price target rate referenc report pleas refer disclosur section recent report regard subject compani charl martineau univers toronto report produc subsidiari affili credit suiss oper global market divis inform structur pleas use follow link http //www credit-suiss com/who-we-ar report may contain materi direct intend distribut use person entiti citizen resid locat local state countri jurisdict distribut public avail use would contrari law regul would subject credit suiss affili cs registr licens requir within jurisdict materi present report unless specif indic otherwis copyright cs none materi content copi may alter way transmit copi distribut parti without prior express written permiss cs trademark servic mark logo use report trademark servic mark regist trademark servic mark cs affili inform tool materi present report provid inform purpos use consid offer solicit offer sell buy subscrib secur financi instrument cs may taken step ensur secur refer report suitabl particular investor cs treat recipi report custom virtu receiv report invest servic contain refer report may suitabl recommend consult independ invest advisor doubt invest invest servic noth report constitut invest legal account tax advic represent invest strategi suitabl appropri individu circumst otherwis constitut person recommend pleas note particular base level taxat may chang inform opinion present report obtain deriv sourc believ cs reliabl cs make represent accuraci complet cs accept liabil loss aris use materi present report except exclus liabil appli extent liabil aris specif statut regul applic cs report reli upon substitut exercis independ judgment cs may issu may futur issu commun inconsist reach differ conclus inform present report commun reflect differ assumpt view analyt method analyst prepar cs oblig ensur commun brought attent recipi report invest refer report offer sole singl entiti case invest sole cs associ cs cs may market maker invest past perform taken indic guarante futur perform represent warranti express impli made regard futur perform inform opinion estim contain report reflect judgment origin date public cs subject chang without notic price valu incom secur financi instrument mention report fall well rise valu secur financi instrument subject exchang rate fluctuat may posit advers effect price incom secur financi instrument investor secur adr valu influenc currenc volatil effect assum risk structur secur complex instrument typic involv high degre risk intend sale sophist investor capabl understand assum risk involv market valu structur secur may affect chang econom financi polit factor includ limit spot forward interest exchang rate time matur market condit volatil credit qualiti issuer refer issuer investor interest purchas structur product conduct investig analysi product consult profession advis risk involv make purchas invest discuss report may high level volatil high volatil invest may experi sudden larg fall valu caus loss invest realis loss may equal origin invest inde case invest potenti loss may exceed amount initi invest circumst may requir pay money support loss incom yield invest may fluctuat consequ initi capit paid make invest may use part incom yield invest may readili realis may difficult sell realis invest similarli may prove difficult obtain reliabl inform valu risk invest expos report may provid address contain hyperlink websit except extent report refer websit materi cs cs review site take respons content contain therein address hyperlink includ address hyperlink cs websit materi provid sole conveni inform content websit way form part document access websit follow link report cs websit shall risk report issu distribut european union except switzerland credit suiss secur europ limit one squar london england authoris prudenti regul author regul financi conduct author prudenti regul author germani credit suiss deutschland aktiengesellschaft regul bundesanstalt fuer finanzdienstleistungsaufsicht bafin ed state canada credit suiss secur usa llc switzerland credit suiss ag brazil banco de investimento credit suiss brasil affili mexico banco credit suiss mxico institucin de banca mltipl grupo financiero credit suiss mxico de bolsa credit suiss mxico de grupo financiero credit suiss mxico credit suiss mexico document prepar inform purpos exclus distribut mexico institut investor credit suiss mexico respons onward distribut report non-institut investor third parti author report receiv payment compens entiti compani relev credit suiss group compani employ japan credit suiss secur japan limit financi instrument firm director-gener kanto local financ bureau kinsho member japan secur dealer associ financi futur associ japan japan invest advis associ type ii financi instrument firm associ hong kong credit suiss hong kong limit australia credit suiss equiti australia limit thailand credit suiss secur thailand limit regul offic secur exchang commiss thailand regist address abdulrahim place floor rama iv silom bangrak thailand tel malaysia credit suiss secur malaysia sdn bhd singapor credit suiss ag singapor branch india credit suiss secur india privat limit cin regul secur exchang board india research analyst registr inh stock broker registr regist address floor ceejay hous dr worli mumbai india t- south korea credit suiss secur europ limit seoul branch taiwan credit suiss ag taipei secur branch indonesia pt credit suiss sekurita indonesia philippin credit suiss secur philippin inc elsewher world relev authoris affili addit region disclaim australia credit suiss secur europ limit cssel credit suiss intern csi authoris prudenti regul author regul financi conduct author fca prudenti regul author uk law differ australian cssel csi hold australian financi servic licenc afsl exempt requir hold afsl corpor act cth corpor act respect financi servic provid australian wholesal client within mean section corpor act hereinaft refer financi servic materi distribut retail client direct exclus credit suiss profession client elig counterparti defin fca wholesal client defin section corpor act credit suiss hong kong limit cshk licens regul secur futur commiss hong kong law hong kong differ australian law cshkl hold afsl exempt requir hold afsl corpor act respect provid financi servic invest bank servic ed state provid credit suiss secur usa llc affili credit suiss group cssu regul ed state secur exchang commiss ed state law differ australian law cssu hold afsl exempt requir hold afsl corpor act respect provid financi servic credit suiss asset manag llc csam authoris secur exchang commiss us law differ australian law csam hold afsl exempt requir hold afsl corpor act respect provid financi servic materi provid sole institut account defin finra rule elig contract particip defin us commod exchang act credit suiss equiti australia limit abn cseal afsl holder australia afsl malaysia research provid resid malaysia authoris head research credit suiss secur malaysia sdn bhd direct queri singapor report prepar issu distribut singapor institut investor accredit investor expert investor defin financi advis regul also distribut credit suiss ag singapor branch oversea investor defin financi advis regul credit suiss ag singapor branch may distribut report produc foreign entiti affili pursuant arrang regul financi advis regul singapor recipi contact credit suiss ag singapor branch matter aris connect report virtu statu institut investor accredit investor expert investor oversea investor credit suiss ag singapor branch exempt compli certain complianc requir financi advis act chapter singapor faa financi advis regul relev notic guidelin issu thereund respect financi advisori servic credit suiss ag singapor branch may provid eu report produc subsidiari affili credit suiss oper global market divis jurisdict cs alreadi regist licens trade secur transact effect accord applic secur legisl vari jurisdict jurisdict may requir trade made accord applic exempt registr licens requir materi issu distribut cssu member nyse finra sipc nfa cssu accept respons content client contact analyst execut transact credit suiss subsidiari affili home jurisdict unless govern law permit otherwis pleas note research origin prepar issu cs distribut market profession institut investor custom recipi market profession institut investor custom cs seek advic independ financi advisor prior take invest decis base report necessari explan content cs may provid variou servic us municip entiti oblig person municip includ suggest individu transact trade enter transact servic cs provid municip view advic within mean section dodd-frank wall street reform consum protect act cs provid servic relat inform sole arm length basi advisor fiduciari municip connect provis servic agreement direct indirect municip includ offici manag employe agent thereof cs cs provid advic municip municip consult financi account legal advisor regard servic provid cs addit cs act direct indirect compens solicit municip behalf unaffili broker dealer municip secur dealer municip advisor invest advis purpos obtain retain engag municip connect municip financi product issuanc municip secur invest advis provid invest advisori servic behalf municip report distribut financi institut credit suiss ag affili financi institut sole respons distribut client institut contact institut effect transact secur mention report requir inform report constitut invest advic credit suiss client distribut financi institut neither credit suiss ag affili respect offic director employe accept liabil whatsoev direct consequenti loss aris use report content inform commun provid herein otherwis intend constru recommend within mean us depart labor final regul defin invest advic purpos employe retir incom secur act amend section intern revenu code amend inform provid herein intend gener inform constru provid invest advic imparti otherwis copyright credit suiss ag and/or affili right reserv purchas non-list japanes fix incom secur japanes govern bond japanes municip bond japanes govern guarante bond japanes corpor bond cs seller request pay purchas price charl martineau univers toronto
